The company says Dormazolam works in synergy with other induction agents to provide an extended duration of anaesthesia without adversely affecting the quality of recovery 2,3,5.
Benzodiazepines are commonly incorporated into anaesthetic regimens to alleviate issues seen with the administration to ketamine alone2,3,4, including inadequate muscle relaxation2,3,4, anaesthesia not lasting long enough2 and induction failure2.
Despite the issues caused by the sole use of ketamine, it remains the primary anaesthetic induction agent of choice for more than 90% of equine vets2.
Dechra Brand Manager Emma Jennings said: “Using Dormazolam as part of an equine anaesthesia protocol will give optimal general anaesthetic conditions every time, including a rapid onset of action1.
"Anaesthetic co-induction with ketamine and midazolam has been shown to provide a superior quality of anaesthesia compared to ketamine alone3 and midazolam is equally as effective as diazepam when used as a co-induction agent alongside ketamine4. It also cuts down on the number of ketamine ‘top-up’ doses required compared to using ketamine3 alone.
"Additional benefits include no clinically significant differences in cardiopulmonary function1 or recovery times1 between midazolam and diazepam and it can be mixed in the same syringe as ketamine for ease of use4.”
Emma added: “The introduction of Dormazolam provides an exciting new option for equine vets. It delivers enhanced anaesthetic and surgical conditions by improving anaesthetic induction quality2,3,4 and giving better surgical relaxation scores2,3,4. It also reduces involuntary movements because, as a co-induction agent, midazolam only causes minimal cardiovascular and pulmonary depression2,4.”
Dormazolam is available in a 20 ml vial. It has a shelf life of four years and a broached shelf life of 28 days.
For more information, visit: www.dechra.co.uk/therapy-areas/equine/anaesthesia/analgesia.
References:
The company says the new product has been 10 years in development and uses 'Soft Mist' technology - developed originally for human use by its pharma business - to deliver medication deep into the horse's lungs.
The active ingredient in the Aservo EquiHaler is ciclesonide, a corticosteroid that is activated directly in the lung, reducing the lower airway inflammation associated with severe equine asthma and reducing the risks commonly associated with systemic corticosteroids.
The Aservo EquiHaler does not use a propellant, so it does not contribute to greenhouse gas emissions. Boehringer also highlights that it is made from up to 50% recycled materials. In April, the product was awarded a Red Dot Design Award.
Dr Marc Laemmer, Head of Equine in UK & Ireland said: "It's another industry first and is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation.
"We understand that a product launch in this challenging time for the veterinary profession may seem surprising, but we have had such strong demand from equine vets for the product that we have committed to making Aservo EquiHaler available. Out team of territory managers and vet advisers will conduct remote meetings with customers to make sure that they have the information and support they require."
Speakers at the free event will include feline expert Dr Andy Sparkes, BVetMed, PhD, DipECVIM, MANZCVS, MRCVS and the immunologist who led the Purina research behind Liveclear, Dr Ebenezer Satyaraj, PhD.
Andy will address the consequences of feline allergy. He says that in majority of cases, cat-allergic owners will choose to tolerate ongoing symptoms of allergy, rather than relinquish their cats, even when they have severe symptoms.
Ebenezer will talk about the research behind Pro Plan Liveclear and how it will allow veterinary surgeons and nurses to help support these clients.
Libby Sheridan, MVB MRCVS, Purina Veterinary Technical Affairs Manager, UK & Ireland said: "This innovation is safe for cats who continue to produce the major cat allergen, Fel d 1, which is found mainly in the cat's saliva and sebaceous glands.
"Our researchers found that the Fel d 1 protein could be neutralised through feeding a nutritious cat food coated with an innovative egg product ingredient containing anti-Fel d 1 antibodies1 which helps reduce the active allergen transferred to hair and dander during grooming, and ultimately helps reduce active Fel d 1 in the environment.2
"Now the science has resulted in a commercially available product that could have a big impact on the quality of life of the cat and their owner. We'll be sharing the research behind this at the symposium so that clinicians can evaluate the potential benefits."
Any member of the practice team can register for the event at www.veterinarywebinars.com/purina, and will be entered into a prize draw to win an iPad. There will also be a number of goody bags available as additional prizes.
More information about the science is available at www.purinainstitute.com.
References
The traditional approach is to use anatomical knowledge to inject pain relief in the area of the nerves to be blocked.
Liz is leading a move away from this approach to a more precise method which uses ultrasound guidance to visualise the nerves, allowing the local anaesthetic to be placed directly around the nerve itself.
For some nerve blocks, it is possible to block just the sensory branches of nerves, which means pets can walk better immediately after surgery while not feeling any pain.
Liz, a past president of the Association of Veterinary Anaesthetists, said: “Local analgesia is now at the forefront of our post-operative care and reliably improves the quality of a pet’s recovery and reduces the need for opioid pain relief, which can cause side effects.
“We’re using the latest techniques to deliver the nerve-blocking anaesthetics to exactly where they’re needed.
“For many of the nerve blocks, the use of ultrasound guidance allows more precise delivery and a complete blockade of the sensory nerves, which is why, here at Paragon, we’ve invested in state-of-the art ultrasound machine designed specifically for superficial and deep nerve blocks.
“This means we can provide more effective immediate post-operative analgesia for our patients and minimise the need for further pain killers.
“The nerves can be directly visualised and local anaesthetic directly placed around the nerve bundles.”
Liz is keen to highlight the advantages of the increased use of local anaesthesia in the treatment of animals. She added: “We’re hoping we’ll soon be able to publish some clinical research on the use of some of the blocking techniques used to demonstrate our clinical impression of their effectiveness in patient management.”
Everyone who takes part in the survey, which is also open to nurses, practice support staff and veterinary students, will be entered into a free prize draw for the chance to win a 1 of 3 Amazon gift vouchers (up to the value of £200).
Lizzie Erian-Round, Head Veterinary Healthcare Advisor at Pegasus (pictured right) said: "With lockdown measures easing, it is a good time to take a deeper dive into what the future looks like. And importantly, how veterinary professionals feel about it. No one has a crystal ball but those on the veterinary frontline are already getting a sense of what could lie ahead. And we believe it’s important they get to share their view of what good support and communications look like.
Our last wave of research indicated that COVID-19 could be a major catalyst for future digital innovation and have lasting consequences for the way we practice. With that in mind we’ve focussed our new survey to be more forward facing."
Pegasus's last survey found that 84% of veterinary professionals thought that the coronavirus pandemic would change the way veterinary practices operate in the future. 78% thought more owners will buy their medicines online. 71% worried about their exposure to coronavirus at their work place and 68% worried about the impact of the pandemic on their mental wellbeing.
The survey closes at 9am GMT Tuesday 30th June The results will help animal health companies better understand how to best support and communicate with the veterinary profession beyond the pandemic.
To take part in the survey, visit: https://www.surveymonkey.co.uk/r/DRWSNWT
For a copy of the results, which will be available in July, email: animal@thisispegasus.co.uk.
Running from 14th-23rd July, the interactive webinars will be delivered in 5 half-day sessions, led by UK pet food consultants, scientists, and vets.
The course includes:
Sarah Hormozi, PFMA Head of Science & Education, said: "With some of the most credible industry experts as our speakers, this is a rare opportunity for pet professionals across the UK and EU to improve and refresh their knowledge of animal nutrition, pet food legislation, marketing regulations and manufacturing methods, from the comfort of their own home or office!”
For the full programme, list of speakers, registration details and prices, visit www.pfma.org.uk/pfma-training-webinar-series.
The university says it has implemented a range of health and safety measures to meet Government guidelines and allow for the controlled return of 150 first-year undergraduate students to its Sutton Bonington campus.
Since the latest cohort joined the university at the height of the UK lockdown, the school has delivered a programme of technology-assisted Fresher’s Week and teaching activities.
However, the return of the April cohort will enable face-to-face teaching that cannot be delivered remotely, specifically essential animal handling and health and safety skills required before students can embark on the work experience element of their course.
The practical sessions will form part of a blended approach to learning, with other lectures and tutorial support continuing to be delivered remotely to reduce the number of students in teaching buildings at any one time.
Dean of the School of Veterinary Medicine and Science Professor Gary England said: “We have missed being on campus with our students tremendously during the coronavirus lockdown and we are excited to be welcoming this cohort to Sutton Bonington in July.
“The health and safety of our students and staff has remained our top priority and has been at the heart of our planning process. Colleagues from across the university have been working intensively on the intricate detail required to ensure that adequate social distancing and hygiene measures are in place to allow this first step in a return to campus.”
Among the measures which have been introduced are:
The university says the return of its vet school cohort and the re-starting of face-to face-education at University of Nottingham Ningbo China at the end of April, where 5,000 students are now back on campus, will form the blueprint for the return of the majority of students to its UK campuses when the new academic term begins on 21 September.
The new devices are an evolution of the original v-gel device launched in 2012, which is widely used in veterinary anaesthesia and resuscitation.
Dr Muhammed Nasir, inventor of v-gel and President of Docsinnovent, said: "Our original product has proven to be extremely popular globally because it makes airway management easier; quicker; more comfortable for patients; and most importantly, safer for patients and staff.
"However, since launch our R&D team have been hard at work to make the devices even better. They are now slimmed down so that there is more room in the mouth for dentistry; they seal even better; and they are single-use, improving standards of hygiene"
Chris Geddes MRCVS, Docsinnovent’s Marketing Manager, added: "Our newly-launched website www.docsinnovent.com includes plentiful information on the new products including two hour-long CPD webinars from Dr Ivan Crotaz detailing how the new devices can be utilised for optimal airway management in anaesthetised patients.”
Information on where to buy the new products can be found at www.docsinnovent.com/distributors
The company says the acquisition is a natural fit for its behavioural range and will bolster its Adaptil portfolio with a wider variety of anxiety solutions for dogs.
Abbie King, senior behaviour product manager at Ceva Animal Health, said: “We have always been fans of the ThunderShirt range and we are therefore delighted with the acquisition, which will further strengthen our extensive portfolio of behavioural products that work in synergy with one another to provide pet owners with comprehensive anxiety solutions.”
For more information, visit: www.thundershirt.com
In an internal study, Royal Canin found that Pill Assist Cat achieved over 91% pill acceptance.
Pill Assist Cat is enriched with vitamins and prebiotics to support a cat’s recovery, and each treat contains only three calories.
Elisabete Capitao, Royal Canin Veterinary Marketing Manager said: "We know that getting cats to take pills can be quite a challenge even for the most experienced pet owners! A quarter of owners leave the veterinary clinic with oral medication for their cat, but 40% find giving pills to their cat complicated. Pill Assist Cat makes giving cats medication easy and takes the stress out of pill time."
Royal Canin says Pill Assist Cat is suitable for most types of medication, from worming tablets to medication for an illness.
The re-categorisation means veterinary practices can sell the topical parasiticides to ‘walk-in clients’ without the need of a prescription.
Andrew Fullerton, veterinary surgeon and product manager at Ceva Animal Health, said: “The new NFA-VPS category for Vectra 3D spot-on solution for dogs and Vectra Felis 423mg/42.3mg spot-on solution for cats provides veterinary practices with greater flexibility to sell easy-to-use, fast and effective parasite prevention and treatment without a prescription."
For more information, contact your Ceva Animal Health account manager or email cevauk@ceva.com.
Backed by RJD Partners, the directors bought the company back from Benchmark Plc for a reported £12.75M after it decided to divest itself of all non-aquaculture-related assets.
Improve says that under its new leadership, it plans to expand its e-learning portfolio significantly, harnessing technologies like video teaching and virtual/augmented reality to offer a richer learning experience.
The company will continue to offer attended modular training options as well as small group practical teaching sessions at its wet labs in Swindon and Sheffield. It says these events will complement its online programmes and will provide stand-alone training for vets wishing to learn new surgical and diagnostic skills.
In collaboration with its assessment partner, the International School of Veterinary Postgraduate Studies (ISVPS), Improve will be developing new distance-learning programmes, together with exams that can be taken remotely.
Improve also plans further geographical expansion, including running programmes in languages including French, Spanish, German and Chinese.
Dr Heber Alves (pictured right) is Improve’s new CEO. He is supported by a management team that includes Improve founder Dr David Babington, Business Development Director and Mr John Douglass, UK Managing Director.
Heber said: “Improve is fully owned by a team of experienced veterinary and business professionals with a unique understanding of the profession’s training needs at a global level. Even better, we are backed by a private equity partner with a strong track record in professional education and a commitment to supporting our growth, both organically and through acquisition.
“We start this new chapter in a world changed irrevocably by COVID-19. It is a world in which veterinary professionals are demanding more flexible ways of learning and showing a hunger to achieve additional qualifications. With this in mind, we will be working to offer a combination of high quality practical, remote and blended learning that will make the achievement of a postgraduate qualification a realistic ambition for every vet."
Mr Wood pleaded guilty to three charges of making indecent images of children at Portsmouth Magistrate’s Court in December 2017. Following his conviction, Mr Wood was given a community sentence, fined and made subject to a sexual harm prevention order for five years.
Mr Wood’s application for restoration was based on the argument that he was professionally competent to be restored to the Register, that he had strong mitigation for his original conviction (for which he had demonstrated remorse), that he had a low chance of reoffending, had engaged proactively with the Probation Service and rehabilitative courses, and that had completed his community service.
In considering Mr Wood’s application, the Disciplinary Committee took into account a number of factors including Mr Wood’s acceptance of the Committee’s original findings, the seriousness of the original findings, protection of the public, the future welfare of animals in his care should he be restored, the length of time off the Register, his conduct since removal from the Register, efforts by Mr Wood to keep up-to-date with his continuing professional development (CPD), the impact of removal from the Register on Mr Wood and public support for his restoration.
However, on balance, the Committee decided that Mr Wood was not currently fit to be restored to the Register.
Ian Arundale, chairing the Committee and speaking on its behalf, said: "In essence, the Committee decided that the facts of the charge justifying removal from the Register and the underlying criminal behaviour were too serious for Mr Wood to be restored at this time. It concluded that because Mr Wood continued to be subject to a sexual harm prevention order, notification requirements for sexual offenders and because he remained on the Barring List by the Disclosure and Barring service until January 2023, he was not fit to be restored to the Register at this time.
"The Committee accepted that Mr Wood had made significant efforts to rehabilitate himself but it was not persuaded that he was fit to be restored to the Register because ancillary orders relating to the underlying criminal offences remained in force. The Committee noted that at the time those orders were made Mr Wood was described as having an addiction and although the Committee accepted that there was a low risk of future reoffending, it decided that because the orders were still in place for public protection reasons, Mr Wood was not fit to be restored to the Register."
The full report of Mr Wood’s restoration hearing can be found at www.rcvs.org.uk/disciplinary
The Stablelab hand-held reader detects and quantifies the biomarker Serum Amyloid A (SAA), an acute phase protein produced by the liver that increases rapidly and dramatically in response to inflammation.
Zoetis says that by measuring SAA, vets can assess the severity of an infection more quickly, often before clinical symptoms start, and are able to monitor the horse’s response over the course of treatment.1
Zoetis vet Wendy Talbot said: “Zoetis is committed to providing vets and horse owners with the most effective health products to better predict, prevent, detect and treat equine disease.
“The Stablelab test kit enables convenient, off-site testing for quick and accurate detection of a reliable indicator of infection in horses.
“Point-of-care testing is one of the fastest-growing areas of diagnostics and this test is rapidly becoming a standard of care in equine practice. SAA testing will help vets to quickly determine an appropriate course of intervention, positively impacting case outcomes.”
For more information, visit: www.stablelab.com. To place an order, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 (option 3).
Reference
The survey was held in mid-June and gathered 196 responses from UK practices. That compared with the 532 responses to the initial survey conducted early in April and 251 responses to the second survey conducted at the start of May.
One of the main findings was a marked increase in the number of practices running a near-normal caseload, from 3% in May to 32% in June. Practice turnover data similarly reflected a shift back towards normality, with 46% now reporting a reduction of less than 25%, compared with 19% last month.
Other findings included:
Lizzie Lockett, RCVS CEO, said: "This latest survey has demonstrated a continuation of the previous survey’s positive trends including an increase in practice turnover with more practices approaching a ‘near normal caseload’ and with a reduction in the number of practices impacted by staff self-isolating or with confirmed cases of Covid-19.
“In this survey we also asked about what difficulties practices may be experiencing with EMS placements for vet students and VN training placements as a result of Covid-19, and this will help us to understand how we can better support students and practices in these areas.
“We will continue to monitor the situation via these regular surveys, with the next one planned for later this summer. I would urge as many practices as possible to continue to complete them, so that we can build up a stronger evidence-base on how veterinary businesses have been affected and how they are recovering.
"This information is not only vital for our own policy decisions but also allows us to present a stronger case to the Government and other public bodies where we wish to influence the decisions they make that will impact the veterinary professions and businesses.”
The survey results can be read in full at www.rcvs.org.uk/coronavirus-resources.
The information has been made available amid concerns from behaviourists and animal welfare organisations that there may be a rise in behavioural issues as lifestyle restrictions are lifted.
The Q&A explains what some of the behavioural concerns are and how they can be prevented and managed. Topics include separation-related issues, animals becoming anxious as the world around them becomes busier and noisier, and puppies lacking appropriate skills when greeting animals (including dogs and people) from other households.
The Q&A can be downloaded here.
Dr Hannah Donovan, vet, clinical animal behaviourist and Social Media Officer at the BVBA said: “We hope that this information will help vets to support their clients and their pets when faced with potential challenges as we transition out of lockdown.”
Professor Ian Ramsey, President of the BSAVA added: “This guidance has been developed in collaboration with the BVBA with the intention of supporting vets in practice in an ever-changing environment. It sits alongside other practical BSAVA resources vets can share with pet owners, such as Vaccination Guidance and Neutering Guidance, and follows the BSAVA’s core ethos – ‘By the profession for the profession.”
The BSAVA has also created a collection of resources for veterinary professionals relating to the prevention, management and treatment of behavioural issues in cats of dogs, which is freely available in the BSAVA Library until the end of July.
The collection includes chapters from the BSAVA Manual of Canine and Feline Behavioural Medicine; for those wishing to buy the full manual, there is a £10 discount on both the print and online editions throughout July (using code BEHAV10 on checkout).
Further information for vets can be found in the BSAVA’s COVID-19 resources here.
Designed to help veterinary practices save clients' time and improve compliance, VetsDeliver supplies Bravecto - the company's 12 week flea and tick treatment - with the wormer of the vet's choice, by post.
Before the pandemic, practices registered clients for the service online or during an appointment and clients would have to collect the first treatments from the practice.
In response to the pandemic, however, MSD has made now it possible for clients to register from home and get their first treatments sent by post.
Amanda Melvin, Marketing Manager for Companion Animals at MSD Animal Health said: "We are all in unchartered territory and we appreciate the pressure veterinary teams are under to continue to care for their clients and local pet community.
"Many businesses are having to add new services to support online facilities and home delivery, and for vets there is also now a need to reduce footfall into practice while still generating income. Making sure effective parasite control is available will help improve compliance as temperatures rise and the risks to the health of our pets increase. It's one less thing for you and your clients to worry about."
For further information, contact your MSD Animal Health account manager or go to www.msd-animal-health-hub.co.uk/vetsdeliver.
In next year's election, there are three places on Council for elected veterinary surgeons, with successful candidates serving four-year terms.
The nomination period runs until 5pm on Friday 31 January 2020. In order to stand, candidates need to complete a nomination form, submit a short biography and personal statement and supply a high resolution digital photo.
Each candidate also needs to have two nominators who need to be veterinary surgeons who are on the RCVS Register but are not current RCVS Council members.
Eleanor Ferguson, RCVS Registrar and Returning Officer said: "As always, we would encourage those who are interested in having their say in some of the key debates in the regulatory sphere, such as our under care review, our policies around the impact of Brexit and our vision for new veterinary legislation, to become a candidate.
"RCVS Council is at its best when it encompasses a broad range of perspectives, experiences and knowledge, and so we encourage people from all areas of veterinary life and all levels of experience to put themselves forward and share their expertise and insight."
Nomination forms, guidance notes and frequently asked questions for prospective RCVS Council candidates can be found at www.rcvs.org.uk/rcvscouncil20.
Prospective candidates for RCVS Council are welcome to contact the Registrar, Eleanor Ferguson (e.ferguson@rcvs.org.uk) and the RCVS CEO, Lizzie Lockett (l.lockett@rcvs.org.uk) for more information about the role of the College and/or RCVS Council.
RCVS Council will also be holding its next public meeting on Thursday 23 January 2020, prior to the closure date for Council candidate nominations. Prospective candidates are welcome to attend the Council meeting as an observer. Contact Dawn Wiggins, RCVS Council Secretary, on d.wiggins@rcvs.org.uk if you wish to attend.
The new editorial team of Ed Hall, David Williams and Aarti Kathrani says the manual has been completely rewritten and reorganised to provide a current, well-structured overview of the main gastrointestinal diseases that challenge both clinical practitioners and academics.
The Manual is divided into four sections:
Diagnostic procedures and techniques: history taking, physical examination, clinical pathology, imaging and biopsy.
Diagnostic approaches to problems: diagnostic approach to complaints/problems affecting the GI tract, pancreas and liver.
Patient management: treatments available for GI, pancreatic and liver disease, including a chapter on fluid and nutritional therapy.
Diseases of specific systems/organs: conditions of organs of the GI tract, including pathophysiology, clinical signs, diagnosis, treatment and prognosis.
Ed Hall said: "The busy small animal practitioner is likely to see a dog or cat with GI signs most days and having this Manual as a resource should give them greater insight into the conditions they are treating and hopefully make their job more satisfying."
The BSAVA Manual of Canine and Feline Gastroenterology is available in a printed edition (£90; £60 to BSAVA members) and an online edition (£75 +VAT; £50 +VAT to BSAVA members).
Inigo’s abstract entitled “Predictive value of cardiac remodelling on survival in dogs with persistent atrial standstill – the UK perspective” sought to determine the survival of dogs in the United Kingdom with persistent atrial standstill (PAS) after pacemaker implantation and the prognostic value of cardiac remodelling. The Congress Programme Committee were impressed by Inigo’s innovative presentation, praising the planning and execution of the multi-centre project.
Ditte’s presentation was entitled “Evaluation of a point-of-care dot Enzyme-Linked Immunosorbent Assay to detect antibodies against canine parvovirus, distemper virus and adenovirus before revaccination”.
Her study described the findings of a prospective non-inferiority study of a point-of-care semi-quantitative titer test performed on canine serum samples and compared to gold standard analysis. Sensitivity, specificity, positive and negative predictive values of the point-of-care titer test were determined for the gold standard titer cut-offs for canine adenovirus, canine distemper virus and canine parvovirus. Ditte was commended by the Congress Programme Committee for the quality of presentation as well as the practical and clinically applicable findings of the study.
The BSAVA Congress Clinical Abstracts, including the winners’ abstracts, are now available to view in the BSAVA Library here: https://www.bsavalibrary.com/content/book/10.22233/9781913859039.
The new Mind Matters Initiative (MMI) Kite App is the result of a collaboration with The Kite Programme. It offers a series of bespoke microlearning modules - known as 'kites' - about mental health and wellbeing.
Microlearning is a type of learning which delivers content in bite-size modules. It usually combines a mixture of interactive activities, images and videos, which can be worked through in as little as five minutes.
The first ‘Kites’ available on the app will cover subjects like breathing activities, mindfulness, time management and physical activity for mental health.
New modules will be added over the weeks and months ahead, in response to feedback from users.
Angharad Belcher, RCVS Director for Advancement of the Professions, said: “Veterinary professionals undertake vital work for animal health and welfare, but the intensity and pressure of their work can take its toll on mental health and wellbeing. Sadly, research shows that compared to the general population, veterinary professionals are more likely to experience mental health distress, including depression and anxiety.
“We recognise how hard it can be for veterinary professionals to fit wellbeing activities into their busy workdays and understand that everyone’s mental health needs are different. By collaborating with The Kite Program, we wanted to create a wellbeing platform that was accessible, flexible and had a range of activities to meet a variety of mental health and wellbeing needs. This app will be another useful tool for the professions, and we are pleased to be able to offer it free of charge.
“We are really looking forward to hearing feedback from the professions about the platform and creating more modules based on their wants and needs.”
The College highlights that users cannot input any personal information into the app and the only data it will hold is a record of active users.
To register for the app, visit: https://www.vetmindmatters.org/mmi-app.
The app will also be demoed at BEVA Congress 2021 (5th-7th September, Birmingham ICC).
The recall was initiated because a visual inspection confirmed the possibility of particulate contamination which is not acceptable for an intravenous use preparation.
The recall is for the following batches only:
108AB Expiry 12/01/2023113H Expiry 16/03/2023
Ceva Animal Health Ltd is contacting veterinary surgeons, retailers and wholesale dealers to examine inventory and quarantine products subject to the recall.
For further information, contact Peter Kyte Business Unit Manager on +44 1494 781510.
The study, titled “Development and progression of proteinuria in dogs treated with masitinib for neoplasia: 28 cases (2010 – 2019)”, also suggests that a urine protein: creatinine greater than 0.5 should prompt reassessment within one week.
For the study, the clinical records of 38 dogs referred to a single university teaching hospital between 2010 and 2019 for treatment of neoplasia with masitinib were retrospectively evaluated.
Data was collected at masitinib initiation and at various timepoints following the start of treatment.
Data gathered included the masitinib dose given and any changes to medication administration or dosing since the previous visit, presence of gross disease and the results of haematology and biochemistry profiles, urinalysis and urine cultures.
Urinalysis results were only included if they were performed at a reference laboratory.
At each timepoint, the urine was classified as non-proteinuric (UP:C ≤0.5) or proteinurinc (UP:C >0.5). Proteinuria was then categorised as likely pre-renal, post-renal, physiological renal or pathological renal.
Dogs were grouped based on the presence or absence of proteinuria at baseline. Non-proteinuric dogs were further divided, based on whether proteinuria developed following treatment during the study.
Of the 28 dogs in the study, five were being treated for epitheliotropic lymphoma, one for vulval lymphoma, one for malignant melanoma and 21 for mast cell tumours.
Twenty-two (79%) dogs were non-proteinuric and six were proteinuric at baseline.
Of the dogs that were non-proteinuric at baseline, four (18.2%) developed proteinuria within one month of treatment initiation. Median time to first detection of proteinuria was 14.5 days (range: 13 to 31).
Of the dogs with pre-treatment proteinuria (n=6), masitinib treatment was discontinued due to lack of efficacy in three dogs, and three were euthanased during treatment, two for disease progression and one for an unknown reason.
Dr Margaux Kuijlaars, corresponding author for the paper, said: “Patients developing proteinuria should be investigated to exclude non-renal causes. This should allow for more informed recommendations on the monitoring and management of proteinuria and further masitinib treatment in these patients to be made. Masitinib treatment can be considered in patients with pre-treatment proteinuria and does not inevitably cause worsening of proteinuria.
“The findings of this study add to the evidence base for the use of masitinib in treating neoplasia in small animal patients. The use of masitinib in dogs in this study was off-licence as C-KIT MCT expression was not determined, and many dogs were treated for other tumours.”
Nicola Di Girolamo, Editor of JSAP, said: “Little is known about which dogs are predisposed to becoming proteinuric following treatment with masitinib for neoplasia. Due to the small number of dogs in this study that developed proteinuria, conclusions about predisposing factors cannot be definitely drawn.
"The findings of this study add to the evidence base and demonstrate the need for larger, prospective trials including a control population and longer period of follow-up.”
The full article can be found in the August issue of the Journal of Small Animal Practice and can be read online here: https://www.onlinelibrary.wiley.com/doi/10.1111/jsap.13305. It is open access and can be freely accessed by anyone.
Tim was the principal veterinary surgeon at Nine Mile Veterinary Group in Wokingham, Berkshire, from its opening in 1985. He grew the business from one vet and three staff to 16 vets and 60 staff, before selling to CVS in 2007.
Thereupon he became the National Veterinary Director for CVS, supporting the business as it grew from 200 to 1200 vets and supporting individual vets and practices with management advice and clinical practice.
In more recent times Tim has been working with a peripatetic surgery group.
Tim has worked at Guide Dogs before: between 1987 and 2007, he was a Centre Veterinary Advisor at the charity’s now-closed site in Wokingham.
Tim said: “Guide dogs are fantastic to work with – they are good-natured and easy to handle, and the owners always have the best interests of the dog at heart. Plus, you know you are helping more than someone’s pet, a working dog making a real difference to a person’s life. A guide dog needs to be happy and healthy to fulfil its role. It all adds up to a very different flavour of vet work.
“I am looking forward to being back, but in a more central role with more strategic responsibility. The veterinary world has changed so much, even in the last ten years, and it will be good to draw on my experiences to help Guide Dogs traverse that change.
“It’s important that we keep the healthcare of guide dogs at the top of the priorities list; the dogs have always been at the very core of the charity. It’s crucial that we have solid relationships with veterinary practices, to ensure our dogs receive the greatest care at the best value to the charity."
The company initiated the recall after identifying a potential for the sterility/stability of the product to be compromised due to a crimping problem of the aluminium cap.
The recall is for the 100 ml bottles of the following batch only:
Batch No.0C3829 Expiry Date 03/12/2022
Vetoquinol UK Ltd is contacting veterinary surgeons and veterinary wholesalers to examine inventory immediately and quarantine products subject to this recall.
For further information, contact the Customer Services Department on +44 1280 814500 Option 1 or email: UK_office@vetoquinol.com.